Nantahala Capital Management LLC Takes $2.36 Million Position in InspireMD, Inc. $NSPR

Nantahala Capital Management LLC acquired a new position in InspireMD, Inc. (NYSE:NSPR) in the second quarter, Holdings Channel.com reports. The fund acquired 3,376,484 shares of the company’s stock, valued at approximately $2,363,876. Nantahala Capital Management LLC owned 0.07% of InspireMD as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NSPR. Parkman Healthcare Partners LLC purchased a new stake in InspireMD in the second quarter valued at about $1,692,000. Velan Capital Investment Management LP raised its position in shares of InspireMD by 137.1% in the 3rd quarter. Velan Capital Investment Management LP now owns 2,143,698 shares of the company’s stock valued at $5,166,000 after purchasing an additional 1,239,669 shares during the last quarter. Orbimed Advisors LLC boosted its stake in InspireMD by 46.9% in the 4th quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock worth $5,577,000 after purchasing an additional 1,000,000 shares in the last quarter. Soleus Capital Management L.P. grew its position in InspireMD by 99.5% during the 2nd quarter. Soleus Capital Management L.P. now owns 1,886,207 shares of the company’s stock worth $4,282,000 after purchasing an additional 940,831 shares during the last quarter. Finally, Ingalls & Snyder LLC increased its stake in InspireMD by 70.8% during the 4th quarter. Ingalls & Snyder LLC now owns 384,300 shares of the company’s stock valued at $684,000 after purchasing an additional 159,298 shares in the last quarter. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on NSPR shares. Piper Sandler reiterated an “overweight” rating and set a $3.00 price target (down from $4.00) on shares of InspireMD in a research note on Tuesday, May 5th. Lake Street Capital set a $4.00 target price on InspireMD in a research report on Monday, May 4th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, InspireMD currently has an average rating of “Buy” and a consensus price target of $4.50.

InspireMD Price Performance

Shares of InspireMD stock opened at $0.85 on Friday. The firm has a fifty day moving average price of $0.75 and a 200 day moving average price of $1.14. InspireMD, Inc. has a 1 year low of $0.63 and a 1 year high of $2.56. The stock has a market cap of $39.52 million, a PE ratio of -1.13 and a beta of 0.81.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.